8-K: Tonix Pharmaceuticals Secures New U.S. Patent for Intranasal Migraine Treatment Tosymra

Tonix Pharmaceuticals has been granted a new U.S. patent for its Tosymra intranasal migraine treatment, further solidifying its market position.

Summary

• Tonix Pharmaceuticals announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,090,139 on September 17, 2024.
• The patent covers a pharmaceutical composition, a method of treating migraine via intranasal administration, and an intranasal delivery system for their marketed product, Tosymra.
• The patent, entitled 'Formulations Comprising Triptan Compounds', is expected to expire in 2030, excluding possible patent term extensions.
• Tosymra (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults.
• The company believes this patent further solidifies Tosymra in the market as a differentiated drug with a differentiated administration method.

Sentiment

Score: 7

Explanation: The document is positive due to the issuance of a new patent, which strengthens the company's intellectual property and market position. However, it also includes standard risk disclosures, which temper the overall sentiment.

Positives

• The new patent provides additional intellectual property protection for Tosymra.
• The patent covers the specific delivery and composition of Tosymra.
• The patent is expected to provide market exclusivity until 2030.
• The patent further differentiates Tosymra in the market.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• The company's actual results could differ materially from those indicated in the forward-looking statements.
• Risks include the failure to obtain FDA clearances or approvals, failure to successfully market products, and the need for additional financing.
• There are risks related to the timing and progress of clinical development of product candidates.
• The company faces uncertainties of patent protection and litigation, government or third party payor reimbursement, and substantial competition.

Future Outlook

The company is focused on submitting a New Drug Application (NDA) to the FDA in October 2024 for TNX-102 SL and continues to develop its pipeline of product candidates.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that the patent further solidifies Tosymra in the market as a differentiated drug with a differentiated administration method.
• He also mentioned that the company is thrilled to have these additional issued patent claims, which add to the intellectual property protection existing for Tosymra.

Industry Context

The announcement is relevant to the pharmaceutical industry, specifically in the area of migraine treatment. The patent strengthens Tonix's position in the market for acute migraine therapies, where there is a significant unmet need.

Comparison to Industry Standards

• The migraine treatment market is competitive, with companies like AbbVie (Ubrelvy, Qulipta), Eli Lilly (Emgality), and Teva (Ajovy) offering various therapies.
• Tonix's Tosymra competes with other triptans, but the intranasal delivery method and new patent may provide a competitive advantage.
• The patent for the delivery system is a key differentiator, as many migraine treatments are oral or injectable.
• The expected patent expiry in 2030 is a standard timeframe for pharmaceutical patents, providing a period of market exclusivity.

Stakeholder Impact

• Shareholders may view the patent issuance positively, as it enhances the value of the company's intellectual property.
• Patients may benefit from the continued availability of Tosymra as a treatment option for migraines.
• The company's employees may be positively impacted by the company's growth and success.

Next Steps

• Tonix plans to submit a New Drug Application (NDA) to the FDA in October 2024 for TNX-102 SL.
• The company will continue to develop its pipeline of product candidates.

Key Dates

Keywords

Tosymra, migraine, patent, intranasal, sumatriptan, pharmaceutical, intellectual property, TNXP